Recent Finacing
Recent Raise
resTORbio develops RTB101, an oral selective TORC1 inhibitor as an immunotherapy to counter immunosenescence, conducting Phase 2b trials (±everolimus) to reduce respiratory tract infections in elderly.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors